Berkshire Hathaway-owned Lubrizol acquires device manufacturer Vesta; LensAR raises $8M;

@FierceMedDev: FDA names 107 devices it will exempt under new guidelines. Report | Follow @FierceMedDev

@StacyALawrence: Smith & Nephew touts acquisitions, offers bulk hospital buying. Story | Follow @StacyALawrence

@VarunSaxena2: Industry, Dems and GOP clash on looming diagnostics regulations. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: FDA loosens regulatory oversight of more digital health devices with new guidance. MedCity News story | Follow @EmilyWFierce

> Lubrizol announced its acquisition of medical devices contract manufacturer Vesta. Lubrizol anticipates that the addition will enhance its life sciences manufacturing abilities. Release

> After another successful funding round, LensAR added $8 million to its previous $10 million of funds raised toward a laser-based cataract surgery system. Report

> Fifteen entrepreneurs from Illinois received grants from the PROPEL Center of the iBIO Institute to help them attend the AdvaMed 2014 MedTech Conference in Chicago. Release

Biotech News

@FierceBiotech: PTC wins EU approval for its DMD drug as Phase III data pend. News | Follow @FierceBiotech

@JohnCFierce: Amgen preps for swift FDA review as Kyprolis/Revlimid combo stymies myeloma. News | Follow @JohnCFierce

@DamianFierce: RT @LifeSciVC: VC-Backed Biotech IPOs: Valuations And Virtuous Cycles [new blog]. Blog | Follow @DamianFierce

> Amgen preps for swift FDA review as Kyprolis/Revlimid combo stymies myeloma. Story

> PTC wins EU approval for its DMD drug as Phase III data pend. Article

> Bristol-Myers is seeding a new crop of biotech spinouts, buyout options included. More

> Biotechs find themselves in R&D spotlight as ebola hits the headlines. Report

Pharma News

@FiercePharma: Friday: U.K. and Novartis begin price negotiations on Bexsero. FierceVaccines story | Follow @FiercePharma

@TracyStaton: Tops at FiercePharma over the weekend: Top Sanofi exec departs amid struggles in #diabetes franchise. Story | Follow @TracyStaton

@EricPFierce: Impax CEO reassures markets after company gets 2nd FDA form 483 in a week. More | Follow @EricPFierce

@CarlyHFierce: Allergan 'insider trading' lawsuit piles uncertainty onto Valeant's takeover try. Article | Follow @CarlyHFierce

> Allergan 'insider trading' lawsuit piles uncertainty onto Valeant's takeover try. Story

> Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. More

> Private equity weighs $10B-plus combo of aging Sanofi, GlaxoSmithKline brands. Report

CRO News

> Genae's expansion binge brings it a U.K. foothold. Item

> Covance dials up revenue but dims its full-year outlook. Report

> Columbia Labs partners up for preclinical services. More

> Pfizer and Roche join Icon's adaptive-trial alliance. Story

> Quintiles ratchets up its expectations after a record quarter. Article

Biotech IT News

> Google providing genomics computing power to DREAM Challenge. Item

> 23andMe to open database to external researchers after securing NIH grant. Report

> Venter hires Google machine learning expert to build Translate for genomics. News

> Medidata strengthens data security through Sumo Logic tie up. Story

> Biopharma searching for right balance in addressing social media use by trial participants. Article

Animal Health News

> Dekkers says Bayer may add to animal health division with M&A, in time. Report

> Merial revenues see sizable jump as NexGard sales are strong in the U.S. More

> Sanofi's Merial releases safe feline rabies vaccine. Item

> Zoetis expands product offerings in key China market. Story

> Merck Animal Health posts small revenue increase, even without Zilmax. Article

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.